Mirus Bio LLC, a biotechnology company in Madison, is being sold to MilliporeSigma, the Burlington, Massachusetts-based U.S. and Canada life science business of Merck KGaA in Darmstadt, Germany, for $600 million.

The deal was announced May 23 by MilliporeSigma and Gamma Biosciences, the live sciences platform of private equity firm KKR that has owned a controlling stake in Mirus Bio since 2021. The transaction is expected to be completed in the third quarter of 2024, subject to U.S. regulatory approvals, as well as other customary closing conditions.

Mirus Bio is a developer and provider of transfection products used in the delivery of genetic material into cells. Transfection is a critical process in the development of certain cell and gene therapies, immunotherapies, and in the editing of genes through CRISPR, among a range of other applications.

Click here to read the full article.